All Articles
Drugging the undruggable: a market readiness analysis for KRAS-G12C

Drugging the undruggable: a market readiness analysis for KRAS-G12C

30 June, 2020

KRAS G12C is a distinctively aggressive, poor survival tumor genotype conferring resistance to anti-EGFR therapies in lung, colorectal (CRC), and pancreatic cancers. Prospective therapies targeting G12C have demonstrated promising activity in Phase I trials.

About Diaceutics

At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - the world’s first Network solution for the development and commercialization of precision medicine diagnostics. 

Diaceutics has worked on every precision medicine brought to market and provides services to 36 of the world’s leading pharmaceutical companies. We have built the world’s largest repository of diagnostic testing data with a growing network of 2500 labs in 51 countries.